Cargando…

Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus

BACKGROUND: This study aimed to evaluate the effect of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, on insulin secretion and glucagon suppression in Korean subjects with type 2 diabetes mellitus. METHODS: Twenty-four subjects underwent a 75-g oral glucose tolerance test (OGTT) before and a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hae Kyung, Kang, Borami, Lee, Seung-Hwan, Kim, Hun-Sung, Yoon, Kun-Ho, Cha, Bong-Yun, Cho, Jae-Hyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543198/ https://www.ncbi.nlm.nih.gov/pubmed/26301196 http://dx.doi.org/10.4093/dmj.2015.39.4.335

Ejemplares similares

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
por: Kim, Ji Hyun
Publicado: (2015)

Triglyceride glucose index, a marker of insulin resistance, is associated with coronary artery stenosis in asymptomatic subjects with type 2 diabetes
por: Lee, Eun Young, et al.
Publicado: (2016)

The Insulin Resistance but Not the Insulin Secretion Parameters Have Changed in the Korean Population during the Last Decade
por: Yang, Hae Kyung, et al.
Publicado: (2015)

Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
por: Kim, Soon Ae, et al.
Publicado: (2011)

Potential of OneTouch Diabetes Management Software System in Real Field for Korean Type 2 Diabetes Patients
por: Kang, Borami, et al.
Publicado: (2016)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
por: Yang, Yeoree, et al.
Publicado: (2016)

Ambient Temperature and Prevalence of Obesity: A Nationwide Population-Based Study in Korea
por: Yang, Hae Kyung, et al.
Publicado: (2015)

Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
por: Han, Kyung‐Ah, et al.
Publicado: (2018)

Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
por: Yang, Hae Kyung, et al.
Publicado: (2019)

Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study
por: Shin, Juyoung, et al.
Publicado: (2012)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
por: Chang, Jin-Sun, et al.
Publicado: (2013)

Sitagliptin Improves Postprandial Hyperglycemia by Inhibiting Glucagon Secretion in Werner Syndrome With Diabetes
por: Watanabe, Kaneyuki, et al.
Publicado: (2013)

HLA and Insulin-Dependent Diabetes Mellitus in Koreans()
por: Rhee, Byoung Doo, et al.
Publicado: (1987)

Response: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)
por: Kim, Soon Ae, et al.
Publicado: (2011)

Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus
por: Chung, Hye Soo, et al.
Publicado: (2011)

Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
por: Kim, Hyun Min, et al.
Publicado: (2015)

Cardiovascular Autonomic Neuropathy Predicts Higher HbA1c Variability in Subjects with Type 2 Diabetes Mellitus
por: Yang, Yeoree, et al.
Publicado: (2018)

Very Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on the Secretion of Insulin, Glucagon, and Incretin Hormones in Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data
por: Murai, Kazuki, et al.
Publicado: (2014)

Obesity, metabolic health, and mortality in adults: a nationwide population-based study in Korea
por: Yang, Hae Kyung, et al.
Publicado: (2016)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
por: Shin, Sooyoung, et al.
Publicado: (2016)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Miller, Shannon A, et al.
Publicado: (2009)

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
por: Mori, Hiroko, et al.
Publicado: (2013)

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
por: Cho, Yong Kyun
Publicado: (2018)

Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus
por: Ojha, Ashutosh, et al.
Publicado: (2019)

Insulin and Glucagon: Partners for Life
por: Holst, Jens Juul, et al.
Publicado: (2017)

Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
por: Kim, Hyun Jin, et al.
Publicado: (2017)

Predicting the Risk of Insulin-Requiring Gestational Diabetes before Pregnancy: A Model Generated from a Nationwide Population-Based Cohort Study in Korea
por: Lee, Seung-Hwan, et al.
Publicado: (2023)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Wan, Heng, et al.
Publicado: (2016)

Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus
por: Le, Tuan Dinh, et al.
Publicado: (2020)

Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus
por: Choe, Eun Yeong, et al.
Publicado: (2012)

Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus
por: Lee, Chi-Ho, et al.
Publicado: (2022)

Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
por: Kubota, Akira, et al.
Publicado: (2012)

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Shigematsu, Erina, et al.
Publicado: (2014)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto, Seitaro, et al.
Publicado: (2015)

Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
por: Zeng, De-kang, et al.
Publicado: (2019)

Papulonodular Lesions in a Patient of Diabetes Mellitus Receiving Sitagliptin and Metformin
por: Agrawal, Prabhat, et al.
Publicado: (2021)

Insulin and glucagon secretions, and morphological change of pancreatic islets in OLETF rats, a model of type 2 diabetes mellitus.
por: Hong, Eun Gyoung, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_4b7a06ucv9flhl7frnrjcndjse